205242-66-6

Basic information

• Product Name: (S)-4-benzyl-2-((benzyloxy)Methyl)Morpholine
• Synonyms: (S)-4-benzyl-2-((benzyloxy)Methyl)Morpholine;(2S)- 2-[(Phenylmethoxy)methyl]-4-(phenylmethyl)morpholine;(S)-2-[(Phenylmethoxy)methyl]-4-(phenylmethyl)morpholine;(S)-4-benzyl-2-((benzyloxy)methyl)morpholine hydrochloride
• CAS NO: 205242-66-6
• Molecular Formula: C₁₉H₂₃NO₂
• Molecular Weight: 297.39142
• Mol File: 205242-66-6.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 415.3±35.0 °C(Predicted)
• Appearance: /
• Density: 1.095
• PKA: 6.26±0.10(Predicted)
• CAS DataBase Reference: (S)-4-benzyl-2-((benzyloxy)Methyl)Morpholine(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-4-benzyl-2-((benzyloxy)Methyl)Morpholine(205242-66-6)
• EPA Substance Registry System: (S)-4-benzyl-2-((benzyloxy)Methyl)Morpholine(205242-66-6)

Safety Data

• Hazardous Substances Data: 205242-66-6(Hazardous Substances Data)

Usage

General Description

(S)-4-benzyl-2-((benzyloxy)Methyl)Morpholine is a chemical compound with the formula C20H23NO2. It is a morpholine derivative that contains both benzyl and benzyloxy groups. (S)-4-benzyl-2-((benzyloxy)Methyl)Morpholine is commonly used in the field of organic synthesis and pharmaceutical research due to its potential as a building block for the synthesis of various biologically active molecules. Its unique structure and functional groups make it a valuable intermediate for the production of drugs and other fine chemicals. Additionally, it may also have potential applications in the field of medicinal chemistry and drug development.

Upstream product

• 2133-07-5 2-(benzylamino)ethyl hydrogen sulfate 
• 2930-05-4 (S)-benzyl glycidyl ether 
• 205242-64-4 (2S)-1(benzylamino)-3-(benzyloxy)propan-2-ol 
• 100-46-9 benzylamine 
• 14618-80-5 (R)-benzyl glycidol 
• 205242-65-5 (S)-4-Benzyl-6-benzyloxymethyl-morpholin-3-one 

Downstream Products

• 919286-71-8 tert-butyl (2S)-2-(bromomethyl)-4-morpholinecarboxylate 
• 135912-25-3 Toluene-4-sulfonic acid (S)-4-trityl-morpholin-2-ylmethyl ester 
• 132073-84-8 (S)-4-trityl-2-hydroxymethylmorpholine 
• 132073-83-7 (S)-morpholin-2-ylmethanol 

Relevant articles and documents

METHODS OF USE FOR INHIBITORS OF AKT ACTIVITY

Invented is the use of 1 H-imidazo[4,5-c]pyridin-2-yl compounds in the treatment of specified cancers.

(R)-(+)-2-[[[3-(morpholinomethyl)-2H-chromen-8-yl]oxy]methyl]morpholine methanesulfonate: A new selective rat 5-hydroxytryptormine(1b) receptor antagonist

In the search for new 5-hydroxytryptamine (5-HT) receptor antagonists it was found that the compound (R)-(+)-2-[[[3-(morpholinomethyl)-2H-chromen-8- yl]oxy]methyl]morpholine methanesulfonate, (R)-25, is a selective rat 5- hydroxytryptamine(1B) (r5-HT(1B)) receptor antagonist. The binding profile showed a 13-fold preference for r5-HT(1B) (Ki = 47 ± 5 nM; n = 3) vs bovine 5-HT(1B) (Ki = 630 nM; n = 1) receptors. The compound had very low affinity for other monoaminergic receptors examined. The r5-HT(1B) receptor antagonism was demonstrated by the potentiation of the K+-stimulated release of [3H]- 5-HT from superfused rat brain slices in vitro, an effect that was antagonized by addition of 5-HT to the superfusion fluid. (R)-25 at 20 mg/kg sc enhanced the 5-HT turnover in four rat brain regions (hypothalamus, hippocampus, striatum, and frontal cortex) with about 40% measured as the 5- HTP accumulation after decarboxylase inhibition with 3- hydroxybenzylhydrazine. At 3 mg/kg sc (R)-25 produced a significant increase in the number of wet dog shakes in rats, a 5-HT(2A)/5-HT(2C) response that was abolished by depletion of 5-HT after pretreatment with the tryptophan hydroxylase inhibitor p-chlorophenylalanine. The observations show that (R)- 25, by inhibiting terminal r5-HT(1B) autoreceptors, increases the 5-HT turnover and the synaptic concentration of 5-HT.